Latest Rituximab Stories
New research report “Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting” elaborated by GBI Research
MarketOptimizer.org adds “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” to its store.
- IMBRUVICA Net Product Revenue Increased to $109.5 million for the Second Quarter of 2014 - SUNNYVALE, Calif., July 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Findings presented at the 2014 World Transplant Congress SAN FRANCISCO, July 30, 2014 /PRNewswire/ -- A study presented at the 2014 World Transplant Congress evaluated the safety and
WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S.
Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe.
MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics,
Marketing Strategies That Educate Payers and Prescribers on Key Benefits of New Drugs Will Maximize Rapid Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON,
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in
- Having no light.